high definition diagnostics℠

Technology Designed to Reveal More

Simoa's revolutionary digital approach to immunoassays allows single molecules to be counted, delivering a roughly 1000-fold increase in sensitivity. This remarkable sensitivity combined with full automation unlocks a world of insight into disease detection, diagnosis, and patient treatment while meeting the demands of today's laboratory.

Quanterix Awarded Grant from GE and the NFL's Head Health Challenge

Paul Chapman, CEO of Quanterix (2nd from left), appears at a press conference with Jeff Immelt, CEO of GE, and NFL Commissioner Roger Goodell (back row, left to right) as they announce Quanterix as a winner of the GE & NFL Head Health Challenge. Photo credit: NFL.

LEXINGTON, MA — January 23, 2014 — Quanterix announced that they have been selected as a winner of the GE and NFL Head Health Challenge from more than 400 entries across 27 countries by a panel of leading healthcare experts in brain research, imaging technologies and advocates for the advancement of brain research. This grant provides funding to help further advance development of tests to quickly diagnose traumatic brain injuries through their ultra-sensitive Simoa™ technology that measures molecular signatures (biomarkers) of brain injury in blood.

For more information, contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. .

Unprecedented Sensitivity

1000 times greater sensitivity than conventional immunoassays.   Learn More.

Robust Multiplexing

Improve efficiencies and stretch samples with up to 10-plex assays.   Learn More.

Complete Automation

Sample in, result out with an intuitive, user-friendly interface.   Learn More.

Watch the Simoa video to learn more